New Product Launches And Biosimilars Will Open Global Healthcare Markets

Published
29 Aug 24
Updated
14 Aug 25
AnalystConsensusTarget's Fair Value
US$13.17
28.3% undervalued intrinsic discount
14 Aug
US$9.44
Loading
1Y
-55.0%
7D
4.8%

Author's Valuation

US$13.2

28.3% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on06 Aug 25
Fair value Decreased 1.25%

Despite improved revenue growth forecasts for Organon, a higher discount rate has outweighed these gains, resulting in a lower consensus price target from $13.33 to $12.60. What's in the News Organon raised full-year 2025 revenue guidance to $6.275–$6.375 billion and slightly improved its nominal revenue growth outlook.